Patents Assigned to BMR Solutions Ltd.
  • Patent number: 9629893
    Abstract: The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: April 25, 2017
    Assignee: BMR Solutions Ltd.
    Inventor: Azim Turdiev
  • Publication number: 20160022758
    Abstract: The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them.
    Type: Application
    Filed: July 30, 2015
    Publication date: January 28, 2016
    Applicant: BMR SOLUTIONS LTD.
    Inventor: Azim TURDIEV
  • Patent number: 9120843
    Abstract: The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: September 1, 2015
    Assignee: BMR Solutions Ltd.
    Inventor: Azim Turdiev
  • Patent number: 8802817
    Abstract: The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: August 12, 2014
    Assignee: BMR Solutions Ltd.
    Inventor: Azim Turdiev
  • Publication number: 20130129689
    Abstract: The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them.
    Type: Application
    Filed: November 20, 2012
    Publication date: May 23, 2013
    Applicant: BMR Solutions Ltd.
    Inventor: BMR Solutions Ltd.
  • Patent number: 8329864
    Abstract: The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them.
    Type: Grant
    Filed: August 1, 2011
    Date of Patent: December 11, 2012
    Assignee: BMR Solutions Ltd.
    Inventor: Azim Turdiev